Due to scheduled maintenance by the Arizona Department of Administration to the state datacenter, azdhs.gov and related services will be unavailable from 10:00 p.m. Friday, November 15, until 10:00 a.m. Saturday, November 16. Thank you for your patience.
The Arizona Electronic Lab Reporting (ELR) for Meaningful Use Workshop on May 17 was a success!
Informational Flyer | Agenda | Workshop Materials: Part 1, Part 2, Part 3
(Session recordings available soon.)
Meaningful Use and Arizona’s Public Health Systems
As a part of the American Recovery and Reinvestment Act, Congress authorized more than $25 billion in incentive payments to hospitals and healthcare providers to facilitate the adoption of meaningful use of certified electronic health records (EHR’s). Incentive payments of up to $44,000 through the Medicare incentive program or $63,750 through the Medicaid incentive program can be made to eligible professionals (EP’s) and hospitals.
To receive incentive payments, providers must meet and maintain a set of meaningful use measures using a certified EHR. Meaningful use employs a three stage approach, with each stage building on the preceding stage. To demonstrate stage one of meaningful use, an eligible professional must comply with 15 “core” requirements and 5 of 10 “menu” requirements. Eligible providers and hospitals must first complete Stage 1 before progressing to Stage 2.
The Arizona Department of Health Services (ADHS) will enable eligible providers and hospitals to meet two of the three public health “menu” options. At this time we are not accepting syndromic surveillance data. The two public health systems supporting meaningful use are Electronic Lab Reporting (ELR) and Arizona State Immunization Information System (ASIIS).
ADHS is currently preparing for accepting data for Stage 2, which requires eligible providers to submit electronic immunization data to ASIIS and gives them an option for submitting syndromic surveillance data and cancer registry data. Eligible hospitals are required to submit immunization data, reportable lab results, and syndromic surveillance data.